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bodleiaAbstract—Previous work has indicated the potential of magnetically functionalized microbubbles to localize and
enhance cavitation activity under focused ultrasound exposure in vitro. The aim of this study was to investigate
magnetic targeting of microbubbles for promotion of cavitation in vivo. Fluorescently labelled magnetic microbub-
bles were administered intravenously in a murine xenograft model. Cavitation was induced using a 0.5-MHz
focused ultrasound transducer at peak negative focal pressures of 1.2–2.0 MPa and monitored in real-time using
B-mode imaging and passive acoustic mapping.Magnetic targeting was found to increase the amplitude of the cavi-
tation signal by approximately 50% compared with untargeted bubbles. Post-exposure magnetic resonance imag-
ing indicated deposition of magnetic nanoparticles in tumours. Magnetic targeting was similarly associated with
increased fluorescence intensity in the tumours after the experiments. These results suggest that magnetic target-
ing could potentially be used to improve delivery of cavitation-mediated therapy and that passive acoustic mapping
could be used for real-time monitoring of this process. (E-mail: eleanor.stride@eng.ox.ac.uk)  2016 The Au-
thors. Published by Elsevier Inc. on behalf of World Federation for Ultrasound in Medicine & Biology. This is an
open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Key Words: Ultrasound, Magnetic microbubbles, Passive acoustic mapping, Cavitation, Drug delivery, Fluores-
cence, Magnetic resonance imaging.INTRODUCTION
Ultrasound (US) has previously been found to have ther-
apeutic benefits for a diverse range of applications
including physiotherapy (Patrick 1966), cancer treatment
(Kremkau 1979), non-invasive surgery (ter Haar 1999)
and enhancement of the delivery of various agents such
as genes (Newman et al. 2001), chemotherapeutics
(Unger et al. 1998) and oncolytic viruses (Carlisle et al.
2013). At lower amplitudes, ultrasound may be used to
temporarily disrupt the blood–brain barrier, facilitating
the delivery of drugs to the central nervous system
(Hynynen et al. 2006), whereas higher-intensity regimesddress correspondence to: Eleanor Stride, Institute of Biomed-
gineering, University of Oxford, Old Road Campus Research
g, Oxford OX3 7DQ, UK. E-mail: eleanor.stride@eng.ox.ac.uk
ata repository: The data from which the results presented in this
are derived may be found at http://dx.doi.org/10.5287/
n:wrw8Xrp24.
3022may be used to deliver drugs to tumours (Lafon et al.
2012) or to facilitate non-invasive surgery by enabling
instigation of tissue fractionation (Roberts et al. 2006)
or ablation (Illing et al. 2005) from outside of the body.
Acoustic cavitation has been found to play a key role
in the bio-effects of ultrasound (Coussios and Roy 2008)
and may be significantly enhanced by the addition of
exogenous cavitation nuclei such as acoustically active
microbubbles (Greenleaf et al. 1998; Miller and
Thomas 1995). Microbubbles are commonly used as
ultrasound contrast agents for imaging (Ferrara et al.
2007) and may also be formulated to provide additional
functionality for diagnosis and therapy. For diagnostic
purposes, the incorporation of iron oxide nanoparticles
into the microbubble formulation can enable them to pro-
vide contrast enhancement in both ultrasound and mag-
netic resonance imaging (MRI) (Liu et al. 2011; Yang
et al. 2009). Alternatively, fluorescent dyes can be used
to render microbubbles fluorescent (Lum et al. 2006;
Patil et al. 2011), allowing tracking of the distribution
Passive mapping with magnetic microbubbles in vivo d C. CRAKE et al. 3023of microbubble components using fluorescence imaging
techniques. Both MRI contrast enhancement and
fluorescence labelling were employed in the study
described here.
To maximise their impact, microbubbles may also be
formulated to incorporate a therapeutic payload (Hua et al.
1993; Lentacker et al. 2009), which will then be released
upon ultrasound exposure at the treatment site. This
effect may be further enhanced if the microbubbles are
targeted to their intended site of action using strategies
such as incorporation of antibodies into the microbubble
shell, thereby allowing specific binding to receptors on
target cells (Villanueva et al. 1998). However, the efficacy
of such biological targeting methods is strongly influenced
by flow conditions (Takalkar et al. 2004) and requires the
microbubbles to come within very short distances (on the
order of nanometres) of their intended site (Ham et al.
2009). Targeting on greater length scales may be achieved
by applying an external stimulus, such as by exploiting
acoustic radiation forces (Dayton et al. 1999). Alterna-
tively, incorporation of magnetic material such as iron ox-
ide nanoparticles into the microbubble formulation can
enable localisation using a magnetic field (Plank et al.
2005). Such methods were used in this study to facilitate
magnetic targeting of microbubbles.
In previous work, magnetic microbubbles (MMBs)
were reported to enhance ultrasound-mediated gene de-
livery both in vitro (Mannell et al. 2012; Stride et al.
2009; Vlaskou et al. 2010b) and in vivo (Mulvana et al.
2010; Vlaskou et al. 2010a). However, the underlying
mechanisms were not explored in detail; in particular,
acoustic monitoring in previous studies was limited. In
a recent study by the authors, it was found that magnetic
localisation of microbubbles was associated with
increased cavitation activity in vitro, assessed using pas-
sive acoustic mapping (PAM) of their acoustic emissions
(Crake et al. 2015). The purpose of the present study was
to establish whether similar effects could be observed in
the cavitation behaviour of magnetic microbubbles
in vivo and to assess the distribution of microbubble com-
ponents using fluorescence methods and MRI.METHODS
Magnetic microbubble production
1,2-Distearoyl-sn-glycero-3-phosphocholine dis-
solved in chloroform (DSPC, 25 mg/mL) was purchased
fromAvanti Polar Lipids (Alabaster, AL, USA). Polyoxy-
ethylene-40-stearate (PEG), chloroform, glycerol and
propylene glycol were purchased from Sigma Aldrich
(Gillingham, Dorset, UK). 1,1’-Dioctadecyl-3,3,3’,3’-
tetramethylindocarbocyanine perchlorate (DiI) stain and
phosphate-buffered saline (PBS) were purchased from
Life Technologies (Paisley, UK). FluidMAG-Lipid(25 mg/mL 50-nm spherical phosphatidylcholine-coated
magnetite particles in sterile water) was purchased from
Chemicell (Berlin, Germany). Sulphur hexafluoride
(SF6) was purchased from BOC (Guildford, UK).
PEG was dissolved in chloroform (10 mg/mL) using
a bath sonicator. DiI was dissolved in chloroform
(2.5 mg/mL). DSPC and PEG solutions were mixed in a
9:1 molar ratio (61 mL of 25 mg/mL DSPC solution,
44 mL of 10 mg/mL PEG solution) in a glass vial. Glass
precision syringes (Hamilton Microliter; Sigma-
Aldrich, Gillingham, Dorset, UK) were used to measure
solutions for chloroform resistance. For fluorescence
labelling of the MMBs, 20 mL of DiI solution was added
to the mixture, and the vial was left on a hot plate at 50C
for 12 h in a fume hood to allow the chloroform to evap-
orate. The resulting lipid film was resuspended in 1.5 mL
of a solution consisting of 80% PBS, 10% glycerol and
10% propylene glycol on a hot plate at 70Cwith constant
stirring for 20 min. The solution was then sonicated for
60 s to disperse the lipids using an ultrasonic cell disrup-
tor (tip fully immersed, power setting 2; Model XL 2000,
3-mm probe diameter, 22.5 kHz, Misonix, Farmingdale,
NY, USA). Fifteen microliters of FluidMAG-Lipid solu-
tion was added to the vial, and sonication was repeated for
10 s. To produce microbubbles, the probe tip was moved
to the air–liquid interface, and sonication was repeated
for 10 s (power setting 15) while SF6 was continuously
delivered from the gas cylinder to the vial via a tube
held close to the vial opening. After sonication, the vial
was immediately sealed using a pierceable stopper and
stored on ice until used. Experiments commenced within
1 h of sonication.In vitro microbubble characterisation
Sizing.Microbubble size distribution and concentra-
tion were determined via optical microscopy (Model
Eclipse Ti-E, Nikon Instruments, UK) using a 203 objec-
tive lens (Model Plan Fluor, Nikon Instruments, UK). A
20-mL sample of the microbubble suspension was pipet-
ted onto a slide, and 30 images were taken in different lo-
cations. Particle size distribution and concentration were
then determined using purpose-written software
(Sennoga et al. 2010) in MATLAB (The MathWorks, Na-
tick, MA, USA).
Fluorescence labelling. To confirm that the lipo-
philic dye DiI could fluorescently label the microbubbles,
samples were examined using a fluorescence microscope
(Eclipse Ti-E, Nikon Instruments, UK) fitted with a 203
objective (Plan Fluor, Nikon Instruments, Kingston-
upon-Thames, UK), mercury arc light source and TRITC
filter cube. Brightfield and fluorescence images were taken
of the same fields of view.
Fig. 1. Overview of the setup for in vivo experiments (plan
view, not to scale). Tumours were aligned with the focus of a
500-kHz focused ultrasound (FUS) transducer with a rectan-
gular cut-out for a 4- to 11-MHz imaging array. B-Mode imag-
ing was interspersed with passive acoustic recording of the
emissions from cavitation during FUS transducer pulses. Trans-
verse and axial directions are defined relative to the centre of the
front face of the imaging array. Exposures were performed in the
presence of a magnet or non-magnetic bar.
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were magnetically responsive, samples were pipetted
onto a slide without a coverslip (the buoyancy of the mi-
crobubbles against the coverslip was found to impede
motion when a coverslip was used) and examined using
a 43 objective (Plan Fluor). The field of view was posi-
tioned toward one edge of the sample while a 1.5-T per-
manent magnet (N52 grade NdFeB, 10 3 10 3 25 mm;
NeoTexx, Berlin, Germany) was held above the same
side of the slide. Images of the same field of view were
taken in both brightfield and fluorescence modes.
Acoustic response. To confirm that the microbub-
bles were responsive under B-mode and focused ultra-
sound excitation, a simplified version of the
experimental setup for the in vivo work was used (see
below). Ten percent by volume microbubble suspension
or water was placed in a cylindrical sample holder (in-
ternal dimensions: 20-mm diameter 3 20-mm depth)
with acoustically transparent Mylar windows on both
sides to allow for ultrasound propagation. Microbubbles
were delivered using the same-model 29-gauge needle
and insulin syringe as used for the in vivo experiments.
The central volume of the sample chamber was aligned
with the focus of the focused ultrasound (FUS) trans-
ducer in a water tank. B-Mode images were recorded
with the FUS transducer disabled for 10 s over a range
of transmit amplitudes (transmit voltage: 1.6–11.3 V).
B-Mode (6.5-V transmit voltage) and passively recorded
radiofrequency data for PAMwere then acquired for 30 s
with focused ultrasound excitation over a range of am-
plitudes (0–2.0 MPa peak negative focal pressure, 100
cycles per burst).Experimental setup for in vivo work
An overview of the experimental setup is given in
Figure 1. Ultrasound was generated using a 500-kHz
spherically focused single-element FUS transducer
(Model H-107 B-10, Sonic Concepts, Bothell, WA,
USA) with an outer diameter of 64 mm and focal length
of 63 mm and featuring a 453 18-mm rectangular cutout
through which an imaging linear array probe (Model
L11-4 v, Verasonics, Kirkland, WA, USA) with 128 ele-
ments, 38-mm aperture and 4- to 11-MHz bandwidth
was aligned such that the focus of the FUS transducer
was within the imaging plane. Driving waveforms were
generated using a function generator (Model 33250 A,
Agilent, Wokingham, Berkshire, UK) synchronised to
the ultrasound research platform (Model Vantage 256,
Verasonics) using a trigger output signal. The driving
signal was applied to the FUS transducer via a 55-dB po-
wer amplifier (Model 1040 L, Electronics and Innovation,
Rochester, NY, USA) and impedance matching network
supplied by the transducer manufacturer. The ultrasoundresearch platform was connected to a host desktop PC to
configure the imaging sequence, save data and provide
real-time display during experiments.
The FUS transducer and imaging array assembly
were mounted using a three-axis positioning stage in a
40 3 40 3 17-cm acrylic tank filled with filtered, de-
gassed, de-ionised water that was heated to 37C using
an immersion heater. Water quality was maintained dur-
ing experiments by continuous flow through a loop
consisting of a centrifugal pump, de-ionisation column,
10-mm filter and vacuum degassing membrane. That the
degassing process had been successful was tested by
activating the FUS transducer and observing the acous-
tic emissions using the linear array to confirm absence of
cavitation from the water. Before commencing experi-
ments, the focus of the FUS transducer was located us-
ing a 75-mm needle hydrophone (Precision Acoustics,
Dorchester, UK). The location of the hydrophone tip
observed under B-mode imaging was recorded for
display as an overlay on the B-mode image after the hy-
drophone was removed, and used to position tumours at
the focus during experiments. A single rectangular per-
manent magnet (N52 grade NdFeB, 10 3 10 3 25 mm,
NeoTexx, Berlin, Germany) with transversal magnetisa-
tion 1.5 T or non-magnetic stainless-steel bar of the
same dimensions was held in a clamp attached to a
three-axis positioning stage and placed close to the
focus of the FUS transducer. The magnet or bar was
placed at an angle with respect to the ultrasound array
to reduce direct reflection of the ultrasound and creation
of standing waves. A acrylic board attached to a three-
axis positioning stage was used to secure mice and align
tumours with the focus of the FUS transducer under B-
Passive mapping with magnetic microbubbles in vivo d C. CRAKE et al. 3025mode guidance. A nose piece attached to the positioning
board was used for delivery of anaesthetic during the
experiments.
Ultrasound research platform configuration
The ultrasound research platform was configured to
provide B-mode harmonic imaging (4.5-MHz transmit,
9-MHz receive, 48 pulse-inversion pairs per frame, 48
active elements per transmit, 10-cm imaging depth) inter-
leaved with passive recording of the acoustic emissions
from cavitation (array transmit disabled; receive on 128
channels, 35-MHz sample rate, 250-ms recording length)
at an overall frame rate of 0.5 Hz. A trigger output signal
was sent at the beginning of passive recording to the func-
tion generator to initiate focused ultrasound excitation at
the same pulse repetition frequency. Data were trans-
ferred during experiments from the research platform
over a PCI-express bus to a host PC running MATLAB
for real-time display.
B-Mode image reconstruction was accomplished us-
ing compounding of the 96 received signals per frame
with built-in routines supplied by the system manufac-
turer. Passively recorded data were processed using a
1-MHz high-pass digital filter (to attenuate the 0.5-
MHz FUS drive signal) and implementation of the time
exposure acoustics algorithm as previously described
(Gy€ongy and Coussios 2010). Passive maps of 20 3 24
pixels were produced over a 10-mm (transverse) 3 20-
mm (axial) region centred on the focus of the FUS trans-
ducer. B-Mode images, passive acoustic maps and radio-
frequency (RF) data for selected elements were displayed
in real time during experiments. Images and rawRF chan-
nel data were saved to disk for analysis after the
experiments.
Animal model
Animal experiments were conducted in accordance
with UK Home Office guidelines. Balb/c mice (female,
6–8 wk old, mass: 20.0 6 1.3 g; Harlan, UK) were in-
jected subcutaneously with CT26 cells (2 3 105 per
mouse; ATCC; LGC Standards, Teddington, UK) and
allowed to form tumours approximately 100–200 mm3
in size before commencing experiments.
In vivo experimental protocol
Tumours were depilated using depilatory cream
(Veet, Reckitt Benckiser), thoroughly rinsed with water
to prevent trapping of air and outlined with a marker
pen to aid in visual alignment. Mice were anaesthetised
using 5% isoflurane, attached to the positioning board
with tape and maintained under anaesthesia using a
nose piece connected to the positioning board delivering
2% isoflurane. Tail veins were cannulated using a 29-
gauge needle attached to an insulin syringe via a shortlength of 0.3-mm-inner diameter plastic tubing primed
with PBS, such that the syringe could remain outside of
the water tank. Mice were placed vertically in the tank
(head and ears above water surface), and tumours were
aligned with the previously identified FUS transducer
focus under B-mode guidance. The magnet or non-
magnetic bar was positioned close to the tumour at an
angle with respect to the axis of propagation to minimise
disruption of the ultrasound field. Samples of magnetic
microbubbles (150 mL) were drawn through the pierce-
able lid of the vial into an insulin syringe shortly before
the start of each experiment. Each mouse was treated
three times. For each treatment 50 mL of the microbubble
suspension was injected via the tail vein cannula. Be-
tween treatments the FUS transducer and imaging array
assembly were moved by 3 mm in the vertical direction
such that the focus was moved within the tumour.
To begin each experiment, saving of B-mode and
passive data and focused ultrasound excitation where
applicable were simultaneously initiated. After 1 min,
the first 50-mL dose of microbubbles was injected. After
a further 2min, the transducer assembly was moved 3mm
in the vertical direction. The procedure was then repeated
twice, giving three injections per mouse in a total treat-
ment time of 9 min. The ultrasound platform was then
paused to stop treatment, the mice were promptly
removed from the tank, the cannulae were removed and
the mice were allowed to recover in a warm box. At
15 min from the first injection, mice were euthanized
by cervical dislocation, and 20 mL of blood drawn from
the tail vein, which was made up to 200 mL with PBS
and centrifuged for 2 min at 3000 rpm. Plasma and insol-
uble components were frozen separately at 220C. Tu-
mours were harvested and frozen at 220C.
For analysis of the distribution of microbubble com-
ponents using fluorescence measurements, the liver,
spleen, lungs, kidneys, tumour and blood samples were
extracted from six mice after euthanasia 15 min after
treatment with MMBs with or without a magnet and
compared with samples to which known dilutions of
MMBs were added. To investigate clearance kinetics
blood and liver samples were taken from six additional
mice at 10 min from treatment. To establish the in vivo
cavitation threshold for magnetic microbubbles (and
define the ultrasound conditions for the main part of the
study), three mice were treated with MMBs and focused
ultrasound excitation (frequency: 500 kHz, 100 cycles
per burst, 0.5-Hz pulse repetition frequency) at peak
negative focal pressures of 1.2, 1.6 and 2.0 MPa respec-
tively. Next, to evaluate the effects of magnetic targeting
on the cavitation behaviour of MMBs, eight mice were
treated with focused ultrasound (1.6-MPa peak negative
focal pressure) with either MMBs, MMBs 1 magnet,
SonoVue 1 magnet or 24-h-old (depleted) MMBs. A
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ing the magnet. The commercial contrast agent SonoVue
was used as a non-magnetic control in the presence of the
magnet and as a reference for comparison of the cavita-
tion behaviour of MMBs. A 24-h-old sample of MMBs
was used to compare the response and distribution of a
sample with similar chemical composition but depleted
bubble concentration and hence lower acoustic response.
Finally, to evaluate the effects of magnetic targeting on
cavitation-enhanced delivery of dye and magnetic parti-
cles, six mice were treated with either MMBs,
MMBs 1 magnet, SonoVue 1 magnet, 24-h-old
(depleted) MMBs or saline. Two mice (treated with
MMBs 1 magnet or saline) were frozen intact after
euthanasia for whole-body MRI. Tumours were extracted
from the remaining mice for estimation of microbubble
content using fluorescence measurements.
Biological sample processing
Plasma/PBS samples were defrosted, stored on ice
and protected from light. The fluorescence of 100-mL
samples was measured in a black 96-well plate using a
plate reader (excitation: 544 nm, emission: 590 nm,
gain: 2000; FLUOstar Omega, BMG LABTECH, Ayles-
bury, UK) and compared with a standard curve prepared
from known quantities of microbubbles in plasma. Tissue
samples were defrosted, weighed using a balance with
0.1 mg precision (Explorer Pro, OHAUS, N€anikon,
Switzerland) and homogenised in PBS using a rotary ho-
mogenizer (Model T10 basic, IKA, Staufen, Germany) to
a concentration of 200 mg tissue per mL buffer. Samples
were stored on ice and protected from light during the
procedure. The fluorescence of 100-mL samples was
measured and compared with that of standard samples
containing known quantities of microbubbles homoge-
nised in tissue.
Magnetic resonance imaging
MRI was performed at 4.7 T (VNMRS, Varian, Palo
Alto, CA, USA) using a whole-mouse-body quadrature
birdcage transmit–receive coil (Rapid Biomedical, Rim-
par, Germany). Progressively T2*-weighted imaging
was performed using a 3-D multiple gradient echo scan
with echo times, TE 5 3.65, 9.78, 15.91 and 22.04 ms,
repetition time, TR 5 50 ms and flip angle 5 30, at an
isotropic resolution of 211 mm covering a field of
view of 108 3 27 3 27 mm in a scan time of 14 min.
Shimming, frequency offset adjustment and RF pulse
calibration were performed for each sample, and scans
on different samples were operated with the same
receiver gain settings. Images were exported to TIFF files
(512 3 128 3 128 pixels 3 4 echo times; 32 bits per
pixel, 128 MB per file) for analysis in ImageJ (US Na-
tional Institutes of Health, Bethesda, MD, USA). Slicesrevealing the liver and tumour in each mouse were
selected, and the borders of these regions outlined manu-
ally using the freehand selection tool and saved as regions
of interest using the ROI manager feature. The mean and
standard deviation of image intensity in each ROI were
measured at each of the four echo times. To account for
intensity inhomogeneity (Vovk et al. 2007), the results
for liver and tumour were normalised using the mean im-
age intensities in nearby areas of muscle at the same echo
times.PAM post-processing
After the experiments the passively recorded data
were reprocessed over a larger grid (40 3 36 pixels,
20 3 30 mm) using a robust beamforming algorithm
(Coviello et al. 2015) to improve the resolution of map-
ping and ensure all cavitation activity was captured in
the region of interest. The maximum value in each pixel
over the duration of the experiments (indicating
maximum cavitation power) was overlaid in the corre-
sponding location on the B-mode images to produce
representative spatial maps of cavitation activity for
each experiment. The maximum cavitation power was
also extracted from each frame of data to determine the
evolution of cavitation behaviour over time (in particular,
the effects of microbubble injection and destruction). To
produce spectra of the emissions during pressure ramp
experiments, the passively recorded data from the 128
channels in each frame were beamformed to obtain a
trace corresponding to the focal point and then subjected
to a Fourier transform (MATLAB function fft). The
spectra at each time point were averaged over the dura-
tion of the experiments and plotted over the range 0–
10 MHz (toward the upper end of the frequency response
of the ultrasound array, and corresponding to 20 har-
monics of the focused ultrasound excitation frequency).RESULTS AND DISCUSSION
In vitro MMB characterisation
Sizing. The results of microbubble sizing measure-
ments are illustrated in Figure 2a. The measured micro-
bubble concentration of 1.8 3 108 microbubbles/mL
and mean diameter of 3.1 mm were both similar to those
of commercial clinically approved contrast agents (e.g.,
1–5 3 108 microbubbles/mL and 2.5-mm mean diameter
for SonoVue) (Schneider 1999).
Fluorescence labelling. Figure 2b and c are bright-
field and fluorescence images of the same field of view
of a sample of magnetic microbubbles. Comparison of
the two images confirms that the lipophilic dye is at-
tracted to the lipid-based microbubble shells, which are
Fig. 2. In vitromagnetic microbubble (MMB) characterisation. (a) Size distribution plot obtained from 30 images of mag-
netic microbubbles using the image processing software. (b, c) Microscope images of magnetic microbubbles (203
objective): (b) brightfield (33-ms exposure, 13 gain) and (c) fluorescence (TRITC filter, 500-ms exposure, 13 gain) im-
ages of the same field of view. (d) Brightfield and (e) fluorescence (TRITC filter) microscope images of magnetic micro-
bubbles (43 objective) under influence of a magnet. Microbubbles were pipetted into a droplet, and the field of view was
positioned toward the left edge of the droplet. A 1.5-T permanent magnet was held above the left side of the slide and is
visible as the dark region to the left of the brightfield image. Microbubbles were observed to move toward the magnet and
gather on the side of the droplet closest to the magnet under both brightfield and fluorescence imaging. Arrow in (d) in-
dicates direction of microbubblemotion. Inset in (d) depicts the initial distribution of microbubbles in the centre of droplet
before application of magnetic field taken at 13 magnification (bar 5 2000 mm).
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image.
Magnetic response. Microscope images revealing
magnetic microbubbles under the influence of a mag-
netic field are provided in Figure 2d and e. Notably,
the use of a coverslip on the microscope slide was
found to impede microbubble motion, in contrast to
previous work with magnetic microbubbles contain-
ing an oil-based ferrofluid (Crake et al. 2015). Itwas hypothesised that this could be due to the lack
of an oil layer in the new formulation, resulting in
more buoyant microbubbles. For this reason, the mi-
crobubble sample was pipetted onto a slide and left
in a droplet, the microscope field of view being posi-
tioned toward one edge of the droplet. When a 1.5-T
permanent magnet was brought close to the micro-
scope slide, microbubbles were observed to move to-
ward it and gather on this side of the droplet (Fig. 2d).
Observation of the same field of view under
3028 Ultrasound in Medicine and Biology Volume 42, Number 12, 2016fluorescence (TRITC filter) revealed strong emissions
in the same region (Fig. 2e), which suggests success-
ful co-localisation of magnetic particles and fluores-
cent dye within the microbubbles.
Acoustic response. In Figure 3 are B-mode and PAM
images from in vitro measurements of the magnetic mi-
crobubbles in a sample holder. The outline of the sample
holder and reflections from the front and rear Mylar walls
are clearly visible in the B-mode image for the sample
holder containing water (Fig. 3a), with negligible echo
within the chamber. When 10% MMBs were added
(Fig. 3b), a strong increase in image contrast was
observed within the sample chamber.
When the 500-kHz focused transducer was activated
and the PAM data were processed (Fig. 3c, d) only very
low amplitude signals (corresponding to the electrical
noise floor of the system) were observed using water
(Fig. 3c), with a .1000-fold increase in peak power
when MMBs were added (Fig. 3d) (peak power:
0.34 W vs. 0.0002 W). The location of the peak in power
in the maps correlates well with the previously measured
focal point of the FUS transducer, which was positioned
in the centre of the sample chamber.Fig. 3. (a, b) In vitro acoustic testing of magnetic microbubbles
the sample holder is represented by the red dotted box. B-Mode
10% by volume magnetic microbubbles (MMBs). (c, d) In vitro
ultrasound excitation. B-Mode images with passive acoustic ma
(c) water and (d) 10% bDistribution of magnetic microbubbles in vivo
The distribution of magnetic microbubbles in mice
based on fluorescence measurements is illustrated in
Figure 4a. Six mice were injected with magnetic micro-
bubbles without therapeutic ultrasound exposure with
either a magnet or a non-magnetic bar positioned close
to the tumour. Fluorescence readings were converted to
microbubble concentration by use of a standard curve
composed of known microbubble quantities spiked into
blank samples. Concentration measurements for blood
were scaled to obtain total circulating volume based on
the weight of each mouse and assuming 72 mL blood/
kg mouse weight (Diehl et al. 2001). Organ measure-
ments were scaled to total volume in each organ based
on the measured mass of each organ before
homogenisation.
Fluorescence readings indicate that a DiI concen-
tration corresponding to an average of 16% (62%) of
the injected dose was measured in the blood after
15 min, with no significant difference between control
and magnet runs (p 5 0.10). Linear extrapolation
(R2 5 0.999) of the mean result at 10 min (assuming
100% initial value) (Fig. 4b) suggests a clearance
time of around 18 min. This result suggests thatunder B-mode imaging. A region of interest (ROI) within
images for the sample holder containing (a) water and (b)
acoustic testing of magnetic microbubbles under focused
pping (PAM) overlay showing maps of source power for
y volume MMBs.
Fig. 4. Percentage of injected dose in blood and organs of mice following experiments. (a) Distribution in blood and or-
gans at 15 min. Mice were injected with microbubbles while either a magnet (n 5 3) or non-magnetic bar (n 5 3) was
positioned close to the tumour. (b, c) Comparison of percentage doses in blood and liver at 10 and 15 min reveals approx-
imately linear behaviour (R2 values: 0.999 and 0.903, respectively). Means6 standard deviations of all six mice is shown.
Initial doses of 100% and 0% were assumed for blood and liver, respectively.
Passive mapping with magnetic microbubbles in vivo d C. CRAKE et al. 3029microbubble components were still present after
several minutes, which is a practical time scale for
drug delivery applications. Of the major organs, the
highest uptake of MMBs was seen in the liver (mean
36 6 16% of injected dose). Again, the mean result
at 10 min exhibits approximately linear behaviour
(R2 5 0.903, assuming zero initial value) (Fig. 4c).
This is in line with previous work using magnetic nano-
droplets (Cheng et al. 2013) and microbubbles
(Barrefelt et al. 2013) that revealed high uptake of
similar particles in the liver, which is believed to
involve capture by macrophages (in particular Kupffer
cells) in the reticuloendothelial system. Strong uptake
in the liver was also suggested by contrast from the
iron content of the bubbles under MRI (see below).
The dose found in the lungs (mean: 22 6 7%) was
encouragingly low (i.e., of a magnitude similar to that re-
maining in the blood) as microbubbles were delivered via
tail vein injection and so would pass the lungs before
reaching other organs via the systemic circulation. The
lungs have previously been reported to trap microbub-
bles, particularly those of larger size (.20 mm) (Butler
and Hills 1979). A significant reduction (p 5 0.04) was
observed between control and magnet-treated mice,
implying that magnetic targeting may have reduced theproportion of microbubbles trapped in the lungs, perhaps
by retaining some of the larger microbubbles (which
would be both most likely to be trapped in the lungs
and also to contain the greatest quantity of magnetic ma-
terial). Previous in vivo histologic work using similar mi-
crobubbles indicated that the concentration in the lungs is
initially at its peak value before falling (whereas that in
clearance organs such as the liver and spleen rises over
time) (Barrefelt et al. 2013).
The dose found in the spleen in these experiments
was lower than that of the liver (mean 19% 6 2% of in-
jected dose). This is in agreement with previous work
that revealed under histologic analysis that the quantity
of microbubbles in the spleen was initially low, reaching
a peak value after 24 h and declining thereafter (Barrefelt
et al. 2013). Only a small proportion of the injected dose
was found in the kidney (mean: 56 2%), again in agree-
ment with previous studies (Barrefelt et al. 2013; Cheng
et al. 2013). Within the tumours, only a small (but
detectable) average 0.39 6 0.08% of the injected dose
was found. Therapeutic excitation was not used in this
set of experiments so this measurement represents the
background volume of microbubbles or unbound dye
retained in tumour vasculature. Overall for the six mice
it was possible to recover on average 99 6 22% of the
3030 Ultrasound in Medicine and Biology Volume 42, Number 12, 2016injected dose from samples taken. Owing largely to
reductions in the values for liver and lungs, the total
recovery was significantly lower (mean: 83% vs. 117%,
p5 0.03) in magnet-treated mice. The remaining portion
in magnet-treated mice may be accounted for by tissue
that was not sampled in these experiments such as the
skin surrounding the tumour.
In vivo cavitation threshold of magnetic microbubbles
B-Mode and PAM data for the in vivo pressure ramp
experiments are illustrated in Figure 5. At 1.2 MPa peak
negative focal pressure (Fig. 5a), some cavitation was
observed within the tumour (peak power: 29.2 mW).Fig. 5. B-mode and passive acoustic mapping (PAM) results fo
indicating peak source power for 1.2-, 1.6- and 2.0-MPa peak
(centre) and non-magnetic bar (right) are visible in the B-mod
bar in (c) is an artefact caused by reflection against the metal
Maximum source power and (e) spectra for the three pressur
the three injection points (1, 4 and 7 min) versus background
FFT 5 fast FourieOver the duration of the experiment (Fig. 5d, blue line)
cavitation was sporadic, with minor peaks visible at the
injection times (21.5, 10.8 and 1.5 mW at 1, 4 and
7 min respectively). Spectra of the received signal
(Fig. 5e, blue line) indicated the 500-kHz excitation fre-
quency and harmonics at 1 and 1.5 MHz only.
At 1.6 MPa peak negative focal pressure (Fig. 5b),
the amplitude of cavitation emissions was increased by
a factor of 5 (peak power: 152.9 mW), and clearly distinct
peaks were visible at the injection times (peak values
152.9, 83.0 and 48.7 mWat 1, 4 and 7min) (Fig. 5d, green
line). Spectra of the received signal (Fig. 5e, green line)
now depicted a typical microbubble response (Leightonr in vivo pressure ramp. (a–c) B-Mode with PAM overlay
negative focal pressures. The mouse body (left), tumour
e image. The rightmost area overlapping with the metal
surface which was significant only at this amplitude. (d)
es. (f) Mean and standard deviation of source power at
cavitation 1 min before each injection (0, 3 and 6 min).
r transform.
Passive mapping with magnetic microbubbles in vivo d C. CRAKE et al. 30311994) with multiple harmonic peaks visible up to several
megahertz, smaller ultraharmonic peaks (associated with
stable cavitation) and an increase in the broadband signal
level (associated with inertial cavitation).
Finally, at 2.0 MPa peak negative focal pressure
(Fig. 5c), multiple regions of cavitation were observed
close to the ultrasound focus, with lower peak amplitude
(peak power 81.1 mW) than at 1.6 MPa. The evolution of
this behaviour over time (Fig. 5d, red line) illustrates that
cavitation occurred immediately, even before microbub-
bles were injected, while the spectrum (Fig. 5e, red
line) was dominated by broadband noise.
The results for the three pressure steps may be sum-
marised by extracting the cavitation power after each in-
jection (1, 4 and 7 min) and comparing this with the
background cavitation 1 min before each injection (0, 3
and 6 min). This is illustrated in Figure 5f. A large in-
crease in the mean source power on injection was
observed at 1.6 and 2.0 MPa compared with 1.2 MPa;
however, this was only significantly above the back-
ground response at 1.6 MPa. These results suggest that
increasing the pressure from 1.2 to 1.6 MPa resulted in
a higher-amplitude response, probably because of the
greater treated area (and hence number of microbubbles)
being above the threshold for cavitation. At 2.0 MPa,
cavitation was initiated even without microbubble injec-
tion, implying that the inertial cavitation threshold for tis-
sue was exceeded. This result is commensurate with
previous work in the literature at this frequency
(Hynynen 1991). A pressure of 2.0MPawas therefore un-
suitable for these experiments as the acoustic emissions
were no longer correlated with microbubble injection.
To maximise the signal to noise (and avoid endogenous
cavitation), a 1.6-MPa peak negative focal pressure was
selected for use in subsequent experiments. This is
similar to that employed in previous studies at this fre-
quency using SonoVue (Choi et al. 2014; Coviello et al.
2015).Effect of magnetic targeting on cavitation behaviour
in vivo
The effect of magnetic targeting on the cavitation
behaviour of MMBs in vivo is summarised in Figure 6,
which contains B-mode images with PAM maps for the
pulse containing the highest power response displayed
as an overlay. Under the influence of the magnet, the
maximum source power increased by 29% from
167.9 mW without a magnet to 216.0 mW with a magnet
(Fig. 6a, b), reaching a level similar to that obtained with
SonoVue (227.8 mW) (Fig. 6c). With use of a sample of
MMBs with depleted bubble concentration, the
maximum source power was an order of magnitude lower
(16.5 mW), as expected.Over the six injections per condition (Fig. 6e), mag-
netic targeting significantly increased the level of cavita-
tion power detected within the tumour obtained using
MMB, by .50% (mean: 122.6 mW without a magnet,
186.3 mWwith a magnet, p, 0.01). The mean cavitation
power observed using the commercial contrast agent So-
noVue (232.5 mW) was not significantly higher than that
with MMBs with magnetic targeting (p . 0.05). The
response from the depleted MMB sample remained low
(mean source power: 10.1 mW).
These results suggest that magnetic targeting was
able to increase the local microbubble concentration
in vivo, resulting in approximately 50% higher maximum
cavitation power as observed using PAM. The magnitude
of the effect of targeting was lower than that observed in
previous in vitro studies (ca. 23) (Crake et al. 2015),
which is unsurprising because of the numerous unknown
or adverse factors (flow rate; vascularity; vessel size,
depth and location, etc.) that cannot be readily controlled
in vivo.
The commercial contrast agent SonoVue did result
in a slightly higher peak cavitation power than MMBs,
even with magnetic targeting. This is most likely due to
factors such as unequal microbubble concentration that
could not be controlled within these in vivo experiments
(at the high end, the quoted concentration of 53 108 mi-
crobubbles/mL for SonoVue [Schneider 1999] is more
than 2.5 times that measured for MMBs). Other differ-
ences in formulation such as the components of MMBs
that give them additional functionality over SonoVue
(i.e., iron oxide for targeting and MRI visibility, and fluo-
rescent dye for tracking and as a model payload) could
also have an effect on microbubble response and thus
reduce the cavitation response of MMBs compared with
simpler agents that lack such features. Nonetheless, the
50% increase in cavitation power observed using
MMBs with magnetic targeting suggests a significant in-
crease in local microbubble concentration was achieved,
which could be important for cavitation-enhanced thera-
pies. If the microbubbles were engineered also to deliver
a drug, then the biological effect of targeting could be
magnified as a result of increasing both the power of cavi-
tation (resulting in extravasation of the drug) and its local
concentration as a result of targeting. This hypothesis is
tested in the next section by examining the quantity of
fluorescent dye recovered from tumours after each
experiment.
Effect of magnetic targeting on dose found in tumour
The effect of magnetic targeting on the quantity of
fluorescent dye recovered from tumours after treatment
is summarised in Figure 7. The result for SonoVue (cor-
responding to an implied dose of 0.13 6 0.01%) repre-
sents the background signal caused by such effects as
Fig. 6. Effect of magnetic targeting on cavitation behaviour in vivo. (a–d) B-Mode images with passive acoustic mapping
(PAM) overlay for the pulse with highest power for (a) magnetic microbubbles (MMBs), (b) MMBs 1 magnet, (c) So-
noVue and (d) depleted (24-h-old) MMBs. (e) Maximum source power for six injections per condition for the depleted
(24-h-old) MMBs sample, MMBs, MMBs1 magnet and SonoVue. Mean value is shown over six repeats per condition;
error bars represent standard deviation. Asterisks represent statistical significance assessed using one-way analysis of
variance followed by Tukey multiple comparison test (n.s. 5 not significant; **p , 0.01; comparisons not shown
have p values , 0.001).
3032 Ultrasound in Medicine and Biology Volume 42, Number 12, 2016variability in tissue autofluorescence; all of the measure-
ments taken using MMBs were significantly (p , 0.01)
greater than this background reading. When the depleted
MMB sample was used, the dose found in the tumour
(0.30 6 0.04%) was within the range of the mice in the
distribution study discussed above. When MMBs were
used without a magnet, the dose in the tumour more
than doubled, compared with that for the depleted
MMB sample, to 0.636 0.02%. The addition of a magnet
was accompanied by a significant (p , 0.01) further rise
in fluorescence to a dose of 0.75 6 0.03%.Magnetic resonance imaging
In Figure 8 are magnetic resonance images from
MMB-treated and saline control mice. Slices revealing
the liver and tumour in each of the mice were selected,
and the borders of these regions outlined manually. Under
T2*-weighted imaging, iron oxide content appears as
negative contrast (Chavhan et al. 2009; Na et al. 2009).
This is clearly seen in the liver of the treatment mouse
(Fig. 8a), which appears far darker than that of the control
mouse (Fig. 8b) at a given echo time. This negative
contrast results in a lower mean image intensity within
Fig. 7. Effect of magnetic targeting on dose recovered from
tumour in vivo. Mean dose calculated from fluorescence mea-
surements is shown from three tumour samples for each condi-
tion (magnetic microbubbles [MMBs], depleted [24-h-old]
MMBs, MMBs 1 magnet and SonoVue). Error bars represent
standard deviations. Asterisks represent statistical significance
assessed using one-way analysis of variance followed by Tukey
multiple comparison test (**p , 0.01, ***p , 0.001, compari-
sons not shown have p values , 0.0001).
Passive mapping with magnetic microbubbles in vivo d C. CRAKE et al. 3033the liver and more pronounced decay with increasing
echo time compared with the control mouse (Fig. 8c),
suggesting that a substantial proportion of the magnetic
material from the bubbles is captured by the liver. The
standard deviation of the image intensity within the liver
(Fig. 8c, error bars) also declines with echo time (in
contrast to the control mouse, in which it increases
slightly), suggesting that the magnetic material was ho-
mogenously distributed throughout the organ (therefore
masking the normally inhomogeneous appearance of
the liver seen in the control mouse). These results are in
agreement with previous work with PVA-based micro-
bubbles containing iron oxide that indicated negative
contrast in the liver under T2*-weighted imaging as early
as 10 min from injection (Barrefelt et al. 2013). As out-
lined above, in accordance with this result, substantial
fluorescence from the DiI-stained lipid was also observed
in the liver.
Dark areas of negative contrast were visible over the
central portion of the tumour in the treatment mouse
(Fig. 8d), whereas the control mouse tumour appeared
largely homogenous (Fig. 8e). With increasing echo
time, the mean intensity in the tumour of the treatment
mouse declined compared with that of the control mouse
(in which the mean intensity was approximately flat or
slightly rising) (Fig. 8f). The standard deviation of image
intensity in the treatment mouse (Fig. 8f, error bars) was
greater than that in the control mouse and increased with
echo time because of the inhomogeneous distribution of
magnetic particles. This implies that a detectable quantityof magnetic material from the microbubbles was retained
in the tumour. It should be noted that the ultrasound duty
cycle used in these experiments was very low (0.01%),
and the magnet was not applied to the tumour for 5 min
between the end of experiments and mouse euthanasia.
The inhomogeneous distribution of particles in the
tumour and clustering around the centre are also notable,
as these coincide with the region exposed to both ultra-
sound and the magnetic field.
Summary and limitations
The results presented here suggest that magnetic
targeting was able to increase the magnitude of
microbubble-induced cavitation, and this resulted in
deposition of a greater quantity of microbubble compo-
nents in the tumour. Previous studies have attributed
such effects to extravasation (Bazan-Peregrino et al.
2013) and/or microscopic vessel damage (Hwang et al.
2006) as a result of inertial cavitation: The spectra of
cavitation emissions observed in these in vivo experi-
ments were broadband in nature, suggesting this could
be the dominant mechanism here. MMBs resulted in
cavitation with maximum amplitude similar to that of
SonoVue, and were associated with a significant
(twofold) increase in the MMB dose calculated from
fluorescence measurements compared with depleted
samples with lower acoustic response. The addition of
a magnet resulted in a modest increase in the peak cavi-
tation power, suggesting that magnetic targeting was
able to transiently increase the local microbubble con-
centration, resulting in higher instantaneous cavitation
power.
Although the results presented here are promising
and magnetic targeting was found to significantly in-
crease both cavitation power and deposition of material
in the tumours, in absolute terms the percentage of in-
jected dose recovered (and incremental change in this
with targeting) remained small. There are several poten-
tial reasons for this which could be optimised in future
studies to improve the efficacy of the magnetic targeting
protocol and subsequent delivery:
First, the ultrasound conditions used were particu-
larly mild in this study (100 cycles per burst at 0.5-Hz
PRF, duty cycle 0.01%) compared with duty cycles of
6–90% employed in previous studies that aimed to explic-
itly promote extravasation (Bazan-Peregrino et al. 2012).
As the primary aim of this study was not extravasation,
but rather establishment of whether a new MMB formu-
lation could promote cavitation in vivo (no therapeutic
agent was used at this stage), this shorter burst length
was intended to reduce microbubble destruction by ultra-
sound and therefore improve circulation time. However,
the rapid decline in cavitation response after injection
observed in vivo (Fig. 5d) and the relatively similar
Fig. 8. (a–c) Magnetic resonance imaging and analysis for liver of (a) treated mouse and (b) control mouse (echo
time 5 9.78 ms) (c) Normalised intensity and standard deviation in liver region of interest (ROI) for treatment mouse
and control mouse versus echo time. (d–f) Magnetic resonance images and analysis for tumour of (d) treated mouse
and (e) control mouse (echo time 5 15.91 ms). (f) Normalised intensity and standard deviation in tumour ROI for treat-
ment mouse and control mouse versus echo time. ROIs are represented by red outlines in the images.
3034 Ultrasound in Medicine and Biology Volume 42, Number 12, 2016response of SonoVue in the same setup using 50,000 cy-
cle pulses (vs. 100 cycles here) (Graham 2014) suggest
that biological clearance mechanisms are by far the domi-nant factor. These findings should be considered in the
design of future studies to maximise the impact of the mi-
crobubbles during their circulation time, for instance, by
Passive mapping with magnetic microbubbles in vivo d C. CRAKE et al. 3035increasing the burst length and/or PRF over a shorter total
treatment time.
Second, the magnet used for targeting was in this
case a single permanent magnet of high strength and
approximately the same size as the tumours. The magnet
was manually positioned close to the tumours, where its
position was further constrained by the requirement to
avoid excessive interference with the ultrasound field.
Such an arrangement is likely not optimal and could
result in a combination of both ‘‘undertargeting’’ (in
which the field strength in the tumour was too low to opti-
mally retain bubbles) or ‘‘overtargeting’’ (in which bub-
bles were pulled toward the magnet beyond the
intended site, such as into the skin or elsewhere in the
mouse). The solution to this issue is clearly a non-
trivial problem, but could involve more complicated ar-
rangements of permanent magnets (Barnsley et al.
2015) or electromagnets (Mathieu and Martel, 2010) de-
signed to achieve higher field gradients and, thus, greater
targeting efficacy.
Finally, the small needle gauge used to deliver mi-
crobubbles (29 gauge) may also have reduced the effec-
tive microbubble concentration reaching the tumour.
Larger-diameter needles have been reported to preserve
more bubbles (Browning et al. 2011), but this may
come at the expense of more difficult cannula placement
for tail vein injection. Other factors such as the rate of in-
jection may also affect the microbubbles and could be
tested in future studies.
Nonetheless, even subject to the modest ultrasound
conditions and simple magnet used here, a significant in-
crease in both acoustic emissions and fluorescence sug-
gests that ultrasound-induced cavitation of MMBs did
result in extravasation of fluorescent material from the
bubbles and that this could be at least moderately
improved using magnetic targeting. The discrete hypo-
intense regions observed under MRI suggest the same is
true of the microbubbles’ iron content, and confirm that
further study of nanoparticle delivery from microbubbles
with MRI is worthwhile. Optimisation of the ultrasound
and magnetic targeting setup, addition of therapeutic
drugs and investigation of the effects on distribution
and treatment efficacy will be the subject of future
studies.CONCLUSIONS
In this study, the in vivo distribution and ability to
promote cavitation of fluorescently labelled magnetic mi-
crobubbles were investigated in a murine tumour model.
It was found that fluorescence from the microbubbles
could be detected in blood and organs from treated
mice, while their iron content was visible as negative
contrast on MRI. Cavitation was observed using passiveacoustic mapping under focused ultrasound excitation
and found to be comparable to that produced by a com-
mercial contrast agent, with the additional benefits of
facilitating MRI contrast and ability to carry a payload
(here illustrated using a fluorescent dye). Cavitation
induced by the microbubbles and magnetic targeting
were both found to be associated with increased fluores-
cence in excised tumours. This provides evidence both
for the magnetic microbubbles as a means of facilitating
delivery in vivo and for PAM as ameans of non-invasively
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